← Back to Search

Local Anesthetic

Lidocaine for Pain Control During Endovenous Laser Treatments

N/A
Waitlist Available
Research Sponsored by Midwest Vein Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Large Saphenous Vein treatment
Must not have
Liver dysfunction
Patient ineligible for EVLT
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing whether a lower concentration of lidocaine in tumescent anesthesia is just as effective as the standard dose for pain management in endovenous laser treatments, in order to reduce the risk of lidocaine toxicity.

Who is the study for?
This trial is for individuals aged 16-85 in good health who require endovenous laser treatment (EVLT) for varicose veins and can understand the consent process. It's not suitable for those with bleeding disorders, lidocaine sensitivity, liver issues, heart failure or if pregnant.
What is being tested?
The study tests whether a lower concentration of lidocaine in tumescent anesthesia is as effective as the standard dose for pain control during and after EVLT. Participants will be randomly assigned to receive either the standard or reduced dose.
What are the potential side effects?
Potential side effects include symptoms related to lidocaine toxicity such as dizziness, numbness, tingling sensations, confusion or seizures if serum levels become too high.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am receiving treatment for my large saphenous vein.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have liver problems.
Select...
I cannot undergo endovenous laser therapy.
Select...
I have a bleeding disorder.
Select...
I have been diagnosed with congestive heart failure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 1/4 dose lidocaineExperimental Treatment1 Intervention
12.5mL 1% lidocaine in 487.5mL normal saline
Group II: Standard LidocaineActive Control1 Intervention
50mL 1% lidocaine in 450mL normal saline
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lidocaine
FDA approved

Find a Location

Who is running the clinical trial?

Midwest Vein CenterLead Sponsor

Media Library

Lidocaine (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT02192411 — N/A
Pain Research Study Groups: Standard Lidocaine, 1/4 dose lidocaine
Pain Clinical Trial 2023: Lidocaine Highlights & Side Effects. Trial Name: NCT02192411 — N/A
Lidocaine (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02192411 — N/A
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top